{"doi":"10.1016/j.soi.2024.100120","title":"Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma","abstract":"Background and Objectives Talimogene laherparepvec (T-VEC) is an intralesional cancer immunotherapy in patients with unresectable stage IIIB-IV melanoma and Merkel cell carcinoma (MCC). This study assesses T-VEC outcomes in patients with in-transit melanoma and MCC refractory to anti-PD-1 blockade. Methods All patients with advanced melanoma or MCC with ≥ 1 measurable lesion(s) were retrospectively evaluated from 2019 to 2023. Only those who received ICI therapy for ≥ 3 months with progression of regional metastasis prior to receiving T-VEC were included. Clinicopathologic and treatment data were reviewed. Results Seventeen patients underwent T-VEC therapy, consisting of thirteen melanoma and four MCC cases. Median age was 75.9 and 79.6 for melanoma and MCC cases respectively. Eleven melanoma (84 %) and three MCC (75 %) cases received extremity injections. Median number of in-transit metastatic sites for melanoma and MCC were 4 and 10; respectively, and the median number of treatment cycles per patient was five in both groups. Ten total patients responded with 8 complete responses and 2 partial responses, while five (4 melanoma; 1 MCC) had disease progression. Of seventeen patients, two discontinued T-VEC due to grade 3 + adverse events. Conclusion T-VEC following or in conjunction with immunotherapy exhibits tolerability and potential benefit in patients with advanced MCC and melanoma.","journal":"Surgical Oncology Insight","year":2024,"id":482741,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9321,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1000539,"name":"Madeline McNamara","orcid":"0000-0002-5535-539X","position":1,"is_corresponding":false},{"id":1323255,"name":"Margaret A. Kaszycki","orcid":"0000-0002-3486-6609","position":2,"is_corresponding":false},{"id":1100933,"name":"Alexander E. Frey","orcid":null,"position":3,"is_corresponding":false},{"id":322577,"name":"Jeffrey J. Ishizuka","orcid":"0000-0002-4271-7312","position":4,"is_corresponding":false},{"id":793071,"name":"Philippos Apolinário Costa","orcid":"0000-0001-9681-0515","position":5,"is_corresponding":false},{"id":226316,"name":"Thuy Tran","orcid":"0000-0002-6244-7575","position":6,"is_corresponding":false},{"id":226323,"name":"Harriet M. Kluger","orcid":"0000-0002-4932-9873","position":7,"is_corresponding":false},{"id":291535,"name":"James Clune","orcid":"0000-0002-2398-4634","position":8,"is_corresponding":false},{"id":27331,"name":"Sarah A. Weiss","orcid":"0000-0002-1106-7089","position":9,"is_corresponding":false},{"id":291534,"name":"Kelly Olino","orcid":"0000-0001-6209-5218","position":10,"is_corresponding":false},{"id":1166167,"name":"David Su","orcid":"0000-0002-8693-612X","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:07:18.280369Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}